Akero Therapeutics Inc (AKRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Akero Therapeutics Inc (AKRO) has a cash flow conversion efficiency ratio of -0.070x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-67.17 Million) by net assets ($957.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Akero Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
Akero Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Akero Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Akero Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Akero Therapeutics Inc ranked by their cash flow conversion efficiency. See AKRO cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bharat Dynamics Limited
NSE:BDL
|
-0.019x |
|
Steadfast Group Ltd
AU:SDF
|
0.106x |
|
COFCO Tunhe Sugar Co Ltd
SHG:600737
|
0.181x |
|
Sweco AB (publ)
ST:SWEC-B
|
-0.005x |
|
Grupo Elektra S.A.B. de C.V
MX:ELEKTRA
|
0.144x |
|
Hanjaya Mandala Sampoerna Tbk PT
JK:HMSP
|
0.096x |
|
Hainan HNA Infrastructure Investment Group Co Ltd
SHG:600515
|
0.024x |
|
Liberty Broadband Srs C
NASDAQ:LBRDK
|
-0.012x |
Annual Cash Flow Conversion Efficiency for Akero Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Akero Therapeutics Inc from 2017 to 2024. View Akero Therapeutics Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $750.11 Million | $-230.11 Million | -0.307x | -12.96% |
| 2023-12-31 | $535.31 Million | $-145.37 Million | -0.272x | +4.15% |
| 2022-12-31 | $326.56 Million | $-92.52 Million | -0.283x | +39.87% |
| 2021-12-31 | $169.11 Million | $-79.68 Million | -0.471x | -72.17% |
| 2020-12-31 | $258.71 Million | $-70.80 Million | -0.274x | +1.12% |
| 2019-12-31 | $128.73 Million | $-35.63 Million | -0.277x | -398.72% |
| 2018-12-31 | $-49.92 Million | $-4.62 Million | 0.093x | -90.35% |
| 2017-12-31 | $-4.56 Million | $-4.38 Million | 0.960x | -- |
About Akero Therapeutics Inc
Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic… Read more